Improvement of solubility and dissolution rate of Repaglinide by Liquisolid Compact technique: QbD approach

Year 2022, Volume: 26 Issue: 6, 1573 - 1592, 28.06.2025

Mangesh Godbole Amol Thangan Dr. Abhishek Kanugo

https://doi.org/10.29228/jrp.250

Cited By: 3

Abstract

The bioavailability and therapeutic efficacy of several active molecules is limited due to poor solubility. Repaglinide is used to lower plasma glucose levels, especially in type II diabetes mellitus, and its activity is low due to extensive first-pass metabolism and poor solubility. The current research focused on improving the solubility and thus accelerating the dissolution rate of repaglinide for its antidiabetic effect. Liquisolid Compact technique was used for potent therapeutic molecules, which improved the solubility, dissolution rate and thus bioavailability using non-volatile solvents. Repaglinide was readily soluble in PEG 200 at 241 mg/ml. Incorporation of PEG 200 resulted in conversion of solid drug to liquid drug and conversion back to powder form was achieved by incorporation of carrier and coating agents. The compatibility of repaglinide with all excipients was tested by FTIR and the compatibility with excipients was confirmed. Before compression, all powder mixtures were tested for their flow properties such as Carr index and angle of repose, etc. Optimization was performed using Design of Expert, applying 32 Box-Behnken designs consisting of 3 independent parameters (DCP, Aerosil 200 and CP) and reliable parameters (decay and dissolution time). The optimized batch F1 showed good flow properties, low disintegration time and higher dissolution rate of 99.56% within 30 minutes. In addition, the optimized batch successfully passed the stability test.

Keywords

Repaglinide , Liquisolid technique , solubility enhancement , Box Behnken design

References

• [1] Swarup P, Agrawal GP. Solid Dispersion: A Mechanistic and Realistic Approach on Antihypertensive Drug as a Drug Carrier System. Assay Drug Dev Technol. 2021;19(5):282–9. [CrossRef]
• [2] Karole A, Parvez S, Thakur RS, Mudavath SL. Effervescent based nano-gas carrier enhanced the bioavailability of poorly aqueous soluble drug: A comprehensive mechanistic understanding. J Drug Deliv Sci Technol. 2022;69:103167. [CrossRef]
• [3] Butt S, Hasan SMF, Hassan MM, Alkharfy KM, Neau SH. Directly compressed rosuvastatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release. Saudi Pharm J. 2019;27(5):619–28. [CrossRef]
• [4] Thakral NK, Meister E, Jankovsky C, Li L, Schwabe R, Luo L, et al. Prediction of in vivo supersaturation and precipitation of poorly water-soluble drugs: Achievements and aspirations. Int J Pharm. 2021;600:120505. [CrossRef]
• [5] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25. [CrossRef]
• [6] Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. Int J Pharm. 2020;588:119741. [CrossRef]
• [7] Tran P, Park JS. Application of supercritical fluid technology for solid dispersion to enhance solubility and bioavailability of poorly water-soluble drugs. Int J Pharm. 2021;610:121247. [CrossRef]
• [8] Charalabidis A, Sfouni M, Bergström C, Macheras P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Int J Pharm. 2019;566:264–81. [CrossRef]
• [9] Khan KU, Minhas MU, Badshah SF, Suhail M, Ahmad A, Ijaz S. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs. Life Sci. 2022;291:120301. [CrossRef]
• [10] Kanugo A. Liquisolid-pellets technique: A recent technique for enhancing solubility and bioavailability of drugs. Int J Appl Pharm. 2020;12(6):34–40. [CrossRef]
• [11] Agiba AM. Liquisolid Technology: A State-of-the-Art Review on the Current State, Challenges, New and Emerging Technologies for Next Generation. Curr Drug Deliv. 2020;17(9):736–54. [CrossRef]
• [12] Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017;248:71–95. [CrossRef]
• [13] Elkarray SM, Farid RM, Abd-Alhaseeb MM, Omran GA, Habib DA. Intranasal repaglinide-solid lipid nanoparticles integrated in situ gel outperform conventional oral route in hypoglycemic activity. J Drug Deliv Sci Technol. 2022;68:103086. [CrossRef]
• [14] Repaglinide: Uses, Interactions, Mechanism of Action | DrugBank Online. [cited 2022 Feb 27]. Available from: https://go.drugbank.com/drugs/DB00912. [CrossRef]
• [15] Pandey SS, Patel MA, Desai DT, Patel HP, Gupta AR, Joshi SV, et al. Bioavailability enhancement of repaglinide from transdermally applied nanostructured lipid carrier gel: Optimization, in vitro and in vivo studies. J Drug Deliv Sci Technol. 2020;57:101731. [CrossRef]
• [16] Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–83. [CrossRef]
• [17] Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci. 2017;12(1):1–8. [CrossRef]
• [18] Sharma S, Kanugo A, Gaikwad J. Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach. Mater Technol. 2021. [CrossRef]
• [19] Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm. 2007;341(1–2):26–34. [CrossRef]
• [20] Wang D, Xing H, Jiang J, Chen X, Yang T, Wang D, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017;12(2):115–23. [CrossRef]
• [21] Bonthagarala B, Dasari V, Kotra V, Swain S, Beg S. Quality-by-Design based development and characterization of pioglitazone loaded liquisolid compact tablets with improved biopharmaceutical attributes. J Drug Deliv Sci Technol. 2019;51:345–55. [CrossRef]
• [22] Taghizadeh Z, Rakhshani S, Jahani V, Rajabi O, Haghighi HM, Abbaspour M. Preparation and in vitro characterization of carvacrol pellets by combination of liquisolid technique and extrusion-spheronization. J Drug Deliv Sci Technol. 2021;61:102232. [CrossRef]
• [23] Mostafa M, Gardouh AR, Abogresha NM, Gad S. Factorial design, formulation, in vitro and in vivo evaluation of rapid orally disintegrating tablets prepared by sublimation technique using captopril as a model drug. J Drug Deliv Sci Technol. 2020;57:101635. [CrossRef]
• [24] Kanugo AY, Kochar NI, Chandewar AV. Development of Pulsatile Drug Delivery for Chronotherapeutics of Hypertension. Int J Drug Deliv Technol. 2017;7(3):184–9. [CrossRef]
• [25] Prajapat MD, Butani SB, Gohel MC. Liquisolid: A promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine. J Drug Deliv Sci Technol. 2019;53:101135. [CrossRef]
• [26] Dholakiya A, Dudhat K, Patel J, Mori D. An integrated QbD based approach of SMEDDS and liquisolid compacts to simultaneously improve the solubility and processability of hydrochlorthiazide. J Drug Deliv Sci Technol. 2021;61:102162. [CrossRef]
• [27] Jaipakdee N, Tabboon P, Limpongsa E. Application of a liquisolid technique to cannabis sativa extract compacts: Effect of liquid vehicles on the dissolution enhancement and stability of cannabinoids. Int J Pharm. 2022;612:121277. [CrossRef]
• [28] Kazaz Ç, Mesut B, Özsoy Y, Ocak M. Formulation development and evaluation of taste-masked atomoxetine hydrochloride orally disintegrating tablets (Odts). J Res Pharm. 2021;25(5):715–27. [CrossRef]
• [29] Kokott M, Lura A, Breitkreutz J, Wiedey R. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Eur J Pharm Biopharm. 2021;168:122–30. [CrossRef]
• [30] Kanugo AY, Mathur VB. Evaluation and Comparison of Highly Soluble Sodium Stearyl Fumarate with Other Lubricants In Vitro. Indo Am J Pharm Res. 2013;3:4042–4049.
• [31] Han X, Shan X, Du Y, Pang S, Hu L. Development and evaluation of novel innovative multi-channel aripiprazole orally disintegrating tablets. J Drug Deliv Sci Technol. 2020;55:101446. [CrossRef]
• [32] Jaipakdee N, Limpongsa E, Sripanidkulchai B, Piyachaturawat P. Preparation of Curcuma comosa tablets using liquisolid techniques: In vitro and in vivo evaluation. Int J Pharm. 2018;553(1–2):157–68. [CrossRef]
• [33] Kanugo AY, Kochar NI, Chandewar AV, Dhabarde DM, Dhawral VG. Design and evaluation of enteric compression-coated tablet for chronotherapeutic drug delivery. Asian J Pharm. 2017;11(3). [CrossRef]
• [34] Huanbutta K, Yunsir A, Sriamornsak P, Sangnim T. Development and in vitro/in vivo evaluation of tamarind seed gum-based oral disintegrating tablets after fabrication by freeze drying. J Drug Deliv Sci Technol. 2019;54:101298. [CrossRef]